Novel biomarkers for acute radiation injury and countermeasures using large and small animal models and multi-omics approach

Radiat Prot Dosimetry. 2023 Sep 18;199(14):1526-1532. doi: 10.1093/rpd/ncad035.


Threats of radiological or nuclear disasters are of serious concern and a top priority for government agencies involved in domestic security and public health preparedness. There is a need for sensitive bioassays for biodosimetric assessments of radiation exposures originating from unanticipated nuclear/radiological events. The Food and Drug Administration Animal Rule approval pathway requires an in-depth understanding of the mechanisms of radiation injury, drug efficacy and biomarkers for radiation medical countermeasure approval. Biomarkers can be helpful for extrapolating the efficacious countermeasure dose in animals to humans. We summarised here our studies to identify candidate biomarkers for the acute radiation injury using various omic platforms (metabolomics/lipidomics, proteomics, microbiome and transcriptomics/microRNA) using murine and non-human primate models conducted in our laboratory. Multi-omic platforms appear to be highly useful in assessing radiation exposure levels and for identifying biomarkers of radiation injury and countermeasure efficacy, which can expedite the regulatory approval of countermeasures.

MeSH terms

  • Animals
  • Biomarkers
  • Mice
  • Models, Animal
  • Multiomics
  • Nuclear Medicine*
  • Radiation Injuries* / prevention & control
  • United States


  • Biomarkers